Media headlines about Trinity Biotech PLC (NASDAQ:TRIB) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trinity Biotech PLC earned a news impact score of 0.12 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.9527945013486 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, Zacks Investment Research cut shares of Trinity Biotech PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th.
Trinity Biotech PLC (NASDAQ:TRIB) last posted its quarterly earnings data on Thursday, July 20th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03). Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. The firm had revenue of $25.45 million during the quarter, compared to analysts’ expectations of $24.83 million.
Trinity Biotech PLC Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
What are top analysts saying about Trinity Biotech PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trinity Biotech PLC and related companies.